R. Willemze, E. S. Jaffe, G. Burg, L. Cerroni, B. E. Swerdlow et al., WHO-EORTC classification for cutaneous lymphomas, Blood, vol.105, pp.3768-3785, 2005.

E. Olsen, E. Vonderheid, N. Pimpinelli, R. Willemze, Y. Kim et al., Revisions to the staging and classification of mycosis fungoides and Sezary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC), Blood, vol.110, pp.1713-1722, 2007.

Y. H. Kim, H. L. Liu, S. Mraz-gernhard, A. Varghese, and R. T. Hoppe, Long-term outcome of 525 patients with mycosis fungoides and Sézary syndrome: clinical prognostic factors and risk for disease progression, Arch Dermatol, vol.139, pp.857-866, 2003.

M. Beylot-barry, O. Dereure, B. Vergier, S. Barete, L. Laroche et al., Prise en charge des lymphomes T cutanés: recommandations du Groupe français d'étude des lymphomes cutanés, Ann Dermatol Venereol, vol.137, pp.611-621, 2010.

F. Trautinger, R. Knobler, R. Willemze, K. Peris, R. Stadler et al., EORTC consensus recommendations for the treatment of mycosis fungoides/Sézary syndrome, Eur J Cancer, vol.42, pp.1014-1030, 2006.

B. S. Mann, J. R. Johnson, M. H. Cohen, R. Justice, and R. Pazdur, FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma, Oncologist, vol.12, pp.1247-1252, 2007.

C. Zhang, V. Richon, . Ni-x, R. Talpur, and M. Duvic, Selective induction of apoptosis by histone deacetylase inhibitor SAHA in cutaneous T-cell lymphoma cells: relevance to mechanism of therapeutic action, J Invest Dermatol, vol.125, pp.1045-1052, 2005.

P. Marks, R. A. Rifkind, V. M. Richon, R. Breslow, T. Miller et al., Histone deacetylases and cancer: causes and therapies, Nat Rev Cancer, vol.1, pp.194-202, 2001.

S. S. Ramalingam, M. L. Maitland, P. Frankel, A. E. Argiris, M. Koczywas et al., Carboplatin and Paclitaxel in combination with either vorinostat or placebo for firstline therapy of advanced non-small-cell lung cancer, J Clin Oncol, vol.28, pp.56-62, 2010.

A. M. Traynor, S. Dubey, J. C. Eickhoff, J. M. Kolesar, and K. Schell,

M. S. Huie, Vorinostat (NSC# 701852) in patients with relapsed non-small cell lung cancer: a Wisconsin Oncology Network phase II study, J Thorac Oncol, vol.4, pp.522-526, 2009.

G. Garcia-manero, F. P. Tambaro, N. B. Bekele, H. Yang, F. Ravandi et al., Phase II trial of vorinostat with idarubicin and cytarabine for patients with newly diagnosed acute myelogenous leukemia or myelodysplastic syndrome, J Clin Oncol, vol.30, pp.2204-2210, 2012.

P. N. Munster, K. T. Thurn, S. Thomas, P. Raha, M. Lacevic et al., A phase II study of the histone deacetylase inhibitor vorinostat combined with tamoxifen for the treatment of patients with hormone therapy-resistant breast cancer, Br J Cancer, vol.104, pp.1828-1835, 2011.

M. Duvic, R. Talpur, N. X. Zhang, C. Hazarika, P. Kelly et al., Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL), Blood, vol.109, pp.31-39, 2007.

E. A. Olsen, Y. H. Kim, T. M. Kuzel, T. R. Pacheco, F. M. Foss et al., Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma, J Clin Oncol, vol.25, pp.3109-3115, 2007.

, Common Terminology Criteria for Adverse Events (CT-CAE) Version, 2009.

. Quickreference_5x7 and . Pdf,

M. Duvic, E. A. Olsen, D. Breneman, T. R. Pacheco, S. Parker et al., Evaluation of the long-term tolerability and clinical benefit of vorinostat in patients with advanced cutaneous T-cell lymphoma, Clin Lymphoma Myeloma, vol.9, pp.412-416, 2009.

H. Wada, R. Tsuboi, Y. Kato, M. Sugaya, K. Tobinai et al., Phase I and pharmacokinetic study of the oral histone deacetylase inhibitor vorinostat in Japanese patients with relapsed or refractory cutaneous T-cell lymphoma, J Dermatol, vol.39, pp.823-828, 2012.

R. Dummer, M. Beyer, K. Hymes, M. T. Epping, R. Bernards et al., Vorinostat combined with bexarotene for treatment of cutaneous T-cell lymphoma: in vitro and phase I clinical evidence supporting augmentation of retinoic acid receptor/retinoid x receptor activation by histone deacetylase inhibition, Leuk Lymphoma, vol.53, pp.1501-1508, 2012.

R. W. Robey, A. R. Chakraborty, A. Basseville, V. Luchenko, J. Bahr et al., Histone deacetylase inhibitors: emerging mechanisms of resistance, Mol Pharm, vol.8, pp.2021-2031, 2011.

A. R. Chakraborty, R. W. Robey, V. L. Luchenko, Z. Zhan, R. L. Piekarz et al., MAPK pathway activation leads to Bim loss and histone deacetylase inhibitor resistance: rationale to combine romidepsin with an MEK inhibitor, Blood, vol.121, pp.4115-4125, 2013.